ZA200606152B - 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors - Google Patents

2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors

Info

Publication number
ZA200606152B
ZA200606152B ZA200606152A ZA200606152A ZA200606152B ZA 200606152 B ZA200606152 B ZA 200606152B ZA 200606152 A ZA200606152 A ZA 200606152A ZA 200606152 A ZA200606152 A ZA 200606152A ZA 200606152 B ZA200606152 B ZA 200606152B
Authority
ZA
South Africa
Prior art keywords
aryl
thiazoles
amino
substituted
tyrosine kinase
Prior art date
Application number
ZA200606152A
Inventor
Moussy Alain
Ciufolini Marco
Wermuth Camille
Gielthen Bruno
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of ZA200606152B publication Critical patent/ZA200606152B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
ZA200606152A 2004-01-30 2006-07-25 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors ZA200606152B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54006404P 2004-01-30 2004-01-30

Publications (1)

Publication Number Publication Date
ZA200606152B true ZA200606152B (en) 2007-11-28

Family

ID=34826177

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200606152A ZA200606152B (en) 2004-01-30 2006-07-25 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors

Country Status (12)

Country Link
EP (1) EP1711497A1 (en)
JP (1) JP2007519711A (en)
KR (1) KR20060129413A (en)
CN (1) CN1934107A (en)
AU (1) AU2005209485A1 (en)
BR (1) BRPI0507271A (en)
CA (1) CA2554925A1 (en)
IL (1) IL177007A0 (en)
NO (1) NO20063861L (en)
NZ (1) NZ548884A (en)
WO (1) WO2005073225A1 (en)
ZA (1) ZA200606152B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879575A2 (en) 2005-05-09 2008-01-23 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
BRPI0710548B8 (en) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv c-fms kinase inhibitors, pharmaceutical composition and pharmaceutical dosage form
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2649755C (en) * 2006-04-20 2014-12-02 Janssen Pharmaceutica N.V. Method of inhibiting c-kit kinase
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CN101801964A (en) 2007-05-22 2010-08-11 艾其林医药公司 Heteroaryl substituted thiazoles and their use as antiviral agents
JO3240B1 (en) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
ES2528032T3 (en) 2009-01-16 2015-02-03 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy to prevent, treat or manage metastatic cancer
KR101924247B1 (en) * 2011-07-27 2019-02-22 에이비 사이언스 Oxazole and thiazole derivatives as selective protein kinase inhibitors (C-KIT)
CN103130792B (en) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 A kind of thiazolamine compounds
WO2014008477A2 (en) 2012-07-06 2014-01-09 Duke University Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (en) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv Sulfonylation process using nonafluorobutanesulfonyl fluoride
CN103254184B (en) * 2013-05-27 2015-03-18 湖南科技大学 5-substituted-3-[5-hydroxy-4-pyrone-2-yl-methylmercapto]-4-amino-1,2,4-triazole compound and application thereof
CN103319467B (en) * 2013-06-15 2015-10-14 湖南科技大学 A kind of 4-[5-hydroxyl-pyrokomane-2-base methylene is amino]-3-sulfydryl-1,2,4-triazole compounds and purposes
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
EP3439656A4 (en) 2016-04-07 2020-03-11 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004512A3 (en) * 1997-10-27 2003-01-28 Agouron Pharmaceuticals Inc La 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP3222619A1 (en) * 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
HN2002000156A (en) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
IL160329A0 (en) * 2001-08-13 2004-07-25 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
JP4726486B2 (en) * 2002-08-02 2011-07-20 アブ サイエンス 2- (3-Aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
PT1635824E (en) * 2003-06-03 2009-11-24 Novartis Ag 5-membered heterocycle-based p-38 inhibitors

Also Published As

Publication number Publication date
KR20060129413A (en) 2006-12-15
BRPI0507271A (en) 2007-06-26
NZ548884A (en) 2010-06-25
WO2005073225A1 (en) 2005-08-11
NO20063861L (en) 2006-10-23
JP2007519711A (en) 2007-07-19
EP1711497A1 (en) 2006-10-18
AU2005209485A1 (en) 2005-08-11
CN1934107A (en) 2007-03-21
CA2554925A1 (en) 2005-08-11
IL177007A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1794137A4 (en) Specific kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP2040546A4 (en) Tyrosine kinase inhibitors
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
EP1968950A4 (en) Pyrimidine kinase inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL190078A0 (en) Kinase inhibitors
IL183276A0 (en) Kinase inhibitors
IL181169A0 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
EP1954277A4 (en) Aminopyrimidines useful as kinase inhibitors
ZA200900019B (en) Tyrosine kinase inhibitors
EP1581539A4 (en) Novel tyrosine kinase inhibitors
ZA200607648B (en) Kinase inhibitors
EP1778693A4 (en) Tricyclic-heteroaryl compounds useful as kinase inhibitors
SI1943243T1 (en) Kinase inhibitors
EP1713793A4 (en) Pyrimidinone compounds useful as kinase inhibitors
ZA200608775B (en) Monocyclic heterocycles as kinase inhibitors
PL1896422T3 (en) Tyrosine kinase inhibitors
EP1651599A4 (en) Tyrosine kinase inhibitors
EP1951252A4 (en) Tyrosine kinase inhibitors
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors